Αρχειοθήκη ιστολογίου

Αναζήτηση αυτού του ιστολογίου

Τρίτη 4 Απριλίου 2017

Biologics,Biologic Response Modifiers,Biopharmaceutical.

http://otorhinolarygology.blogspot.com/2017/04/biologicsbiologic-response.html

Major kinds of biopharmaceuticals include:

Blood factors (Factor VIII and Factor IX)
Thrombolytic agents (tissue plasminogen activator)
Hormones (insulin, glucagon, growth hormone, gonadotrophins)
Haematopoietic growth factors (Erythropoietin, colony stimulating factors)
Interferons (Interferons-α, -β, -γ)
Interleukin-based products (Interleukin-2)
Vaccines (Hepatitis B surface antigen)
Monoclonal antibodies (Various)
Additional products (tumour necrosis factor, therapeutic enzymes)
Research and development investment in new medicines by the biopharmaceutical industry stood at $65.2 billion in 2008.[11] A few examples of biologics made with recombinant DNA technology include:

USAN/INN Trade name Indication Technology Mechanism of action
abatacept Orencia rheumatoid arthritis immunoglobin CTLA-4 fusion protein T-cell deactivation
adalimumab Humira rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis, psoriasis, Ulcerative Colitis, Crohn's disease monoclonal antibody TNF antagonist
alefacept Amevive chronic plaque psoriasis immunoglobin G1 fusion protein incompletely characterized
erythropoietin Epogen anemia arising from cancer chemotherapy, chronic renal failure, etc. recombinant protein stimulation of red blood cell production
etanercept Enbrel rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis, psoriasis recombinant human TNF-receptor fusion protein TNF antagonist
infliximab Remicade rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis, psoriasis, Ulcerative Colitus, Crohn's disease monoclonal antibody TNF antagonist
trastuzumab Herceptin breast cancer humanized monoclonal antibody HER2/neu (erbB2) antagonist
ustekinumab Stelara psoriasis humanized monoclonal antibody IL-12 and IL-23 antagonist
denileukin diftitox Ontak cutaneous T-cell lymphoma (CTCL) Diphtheria toxin engineered protein combining Interleukin-2 and Diphtheria toxin Interleukin-2 receptor binder
golimumab Simponi rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, Ulcerative colitis monoclonal antibody TNF antagonist


Alexandros Sfakianakis
Anapafseos 5 . Agios Nikolaos
Crete.Greece.72100
2841026182
6948891480

Τετάρτη 21 Δεκεμβρίου 2016

Robustness, flexibility, and sensitivity in a multifunctional motor control model

Abstract

Motor systems must adapt to perturbations and changing conditions both within and outside the body. We refer to the ability of a system to maintain performance despite perturbations as "robustness," and the ability of a system to deploy alternative strategies that improve fitness as "flexibility." Different classes of pattern-generating circuits yield dynamics with differential sensitivities to perturbations and parameter variation. Depending on the task and the type of perturbation, high sensitivity can either facilitate or hinder robustness and flexibility. Here we explore the role of multiple coexisting oscillatory modes and sensory feedback in allowing multiphasic motor pattern generation to be both robust and flexible. As a concrete example, we focus on a nominal neuromechanical model of triphasic motor patterns in the feeding apparatus of the marine mollusk Aplysia californica. We find that the model can operate within two distinct oscillatory modes and that the system exhibits bistability between the two. In the "heteroclinic mode," higher sensitivity makes the system more robust to changing mechanical loads, but less robust to internal parameter variations. In the "limit cycle mode," lower sensitivity makes the system more robust to changes in internal parameter values, but less robust to changes in mechanical load. Finally, we show that overall performance on a variable feeding task is improved when the system can flexibly transition between oscillatory modes in response to the changing demands of the task. Thus, our results suggest that the interplay of sensory feedback and multiple oscillatory modes can allow motor systems to be both robust and flexible in a variable environment.



http://ift.tt/2hWz4lI

Lung Adenocarcinoma with Miliary Metastases and Left Femur Pathologic Fracture: an Unusual Case Mimicking Disseminated Tuberculosis



http://ift.tt/2igAFzu

Highly improved permeation property of thin-film-composite polyamide membrane for water desalination

Abstract

Thin-film-composite (TFC) polyamide membranes with flux-enhancement were prepared by the interfacial polymerization of m-phenylenediamine with trimesoyl chloride on porous polysulfone support. The addition of 1,3-propanesultone (PS) in the organic phase is used to influence the interfacial polymerization process and the morphology of polyamide layer to improve water flux. FTIR, 1H NMR and UV spectra were performed to investigate the effect of PS on interfacial polymerization process. In order to study the forming mechanism of TFC membrane, the resulting TFC membranes were characterized by SEM, AFM, ATR-FTIR, XPS, as well as static contact angle. In comparison with conventional polyamide membrane, the TFC membranes fabricated with PS as the additive exhibit much more improved water flux without NaCl rejection decreasing. Notably, the optimal TFC membrane with 0.04% (wt/v) PS as the additive in organic phase shows the best performance with a NaCl rejection of 99.39% and a water flux of 48.57 L m−2 h−1 at 1.55 MPa, which has increased 41% compared to the value of the conventional TFC membrane.



http://ift.tt/2i1YoUS

Identification of MSH2 inversion of exons 1–7 in clinical evaluation of families with suspected Lynch syndrome

Abstract

Traditional germline sequencing and deletion/duplication analysis does not detect Lynch syndrome-causing mutations in all individuals whose colorectal or endometrial tumors demonstrate mismatch repair (MMR) deficiency. Unique inversions and other rearrangements of the MMR genes have been reported in families with Lynch syndrome. In 2014, a recurrent inversion of MSH2 exons 1–7 was identified in five families suspected to have Lynch syndrome. We aimed to describe our clinical experience in identifying families with this specific inversion. Four probands whose Lynch syndrome-associated tumors demonstrated absence of MSH2/MSH6 staining and who had negative MMR germline testing were evaluated for the MSH2 inversion of exons 1–7, offered during initial genetic workup or upon routine clinical follow-up. All four probands tested positive for the MSH2 inversion. Proband cancer diagnoses included colon and endometrial adenocarcinoma and sebaceous adenoma. A variety of Lynch syndrome-associated cancers were reported in the family histories, although only one family met Amsterdam II criteria. Thirteen at-risk relatives underwent predictive testing. MSH2 inversion of exons 1–7 was found in four probands previously suspected to have Lynch syndrome based on family history and tumor testing. This testing should be offered routinely to patients with tumors demonstrating loss of MSH2/MSH6 staining.



http://ift.tt/2hb10Bb

Tension fecopneumothorax secondary to unrecognized delayed traumatic diaphragmatic hernia

Abstract

Traumatic diaphragmatic hernia is an uncommon but severe problem that is usually seen in patients suffered from blunt or penetrating thoracoabdominal injuries. Despite advances in modern technology, 30–50% of traumatic diaphragmatic ruptures are missed on initial presentation. We report a case of tension fecopneumothorax secondary to an undiagnosed delayed traumatic diaphragmatic hernia in a patient, who sustained blunt trauma chest 15 years back. This case is being presented to emphasize readers that, the diagnosis of diaphragmatic injuries is challenging and requires a high index of clinical suspicion, late presentations are associated with increased morbidity and mortality.



http://ift.tt/2h2VEEK

Cutaneous Side Effects and Transepidermal Water Loss To Gefitinib: A Study of 11 Patients

Abstract

Introduction

Cutaneous side effects caused by epidermal growth factor receptor (EGFR) inhibitors occurred in 45–100% of patients which may lead to therapy modification or interruption. This study aimed to evaluate cutaneous side effects and transepidermal water loss (TEWL) values in non-small cell lung carcinoma (NSCLC) patients who received gefitinib EGFR inhibitor.

Methods

A descriptive observational study with cross-sectional design and a consecutive sampling method was conducted from 1 February to 4 March 2016. Eleven NSCLC patients with EGFR mutation who visited the Hemato-Oncology Clinic/Internal Medicine Department, Dr. Hasan Sadikin General Hospital, Bandung, Indonesia, were assessed through history taking, physical examination, and TEWL examination using Tewameter.

Results

Ten of the eleven patients experienced cutaneous side effects. The most frequently observed was xerosis cutis (8/10 patients), followed by acneiform eruptions (7/10 patients), and paronychia (3/10 patients). None of these patients experienced hair changes, mucositis, or drug hypersensitivity. Mean TEWL value of these patients was higher than normal (11.205 ± 1.881 g/m2/h).

Conclusions

Patients who received gefitinib EGFR inhibitor experienced cutaneous side effects including xerosis cutis, acneiform eruptions, and paronychia, and have mean TEWL values higher than normal. Therefore, it might affect the skin barrier function.



http://ift.tt/2hdEIAw